135 related articles for article (PubMed ID: 26482169)
1. Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Srinivas NR
Clin Pharmacokinet; 2015 Dec; 54(12):1293-5. PubMed ID: 26482169
[No Abstract] [Full Text] [Related]
2. Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Namour F
Clin Pharmacokinet; 2015 Dec; 54(12):1297-8. PubMed ID: 26482170
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
4. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
6. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
7. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
10. Filgotinib in rheumatoid arthritis.
Westhovens R
Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
[TBL] [Abstract][Full Text] [Related]
11. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Namour F; Fagard L; Van der Aa A; Harrison P; Xin Y; Tasset C
Br J Clin Pharmacol; 2018 Dec; 84(12):2779-2789. PubMed ID: 30088677
[TBL] [Abstract][Full Text] [Related]
12. Filgotinib: A Clinical Pharmacology Review.
Namour F; Anderson K; Nelson C; Tasset C
Clin Pharmacokinet; 2022 Jun; 61(6):819-832. PubMed ID: 35637376
[TBL] [Abstract][Full Text] [Related]
13. Filgotinib as rheumatoid arthritis therapy.
Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Van Rompaey L; Galien R; van der Aar EM; Clement-Lacroix P; Nelles L; Smets B; Lepescheux L; Christophe T; Conrath K; Vandeghinste N; Vayssiere B; De Vos S; Fletcher S; Brys R; van 't Klooster G; Feyen JH; Menet C
J Immunol; 2013 Oct; 191(7):3568-77. PubMed ID: 24006460
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.
Singh JA
JAMA; 2019 Jul; 322(4):309-311. PubMed ID: 31334773
[No Abstract] [Full Text] [Related]
16. Filgotinib for the treatment of rheumatoid arthritis.
Taylor PC; Abdul Azeez M; Kiriakidis S
Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
[TBL] [Abstract][Full Text] [Related]
17. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
[TBL] [Abstract][Full Text] [Related]
18. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
19. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Baluom M; Samara E; Grossbard EB; Lau DT
J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.
Knoll BM
J Antimicrob Chemother; 2014 Dec; 69(12):3441-3. PubMed ID: 25114167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
